抗癌药并非对所有老年癌症患者耐受良好
本文指出,关于新型抗癌药物的研究常不恰当地得出这些治疗在老年癌症人群中耐受良好且可行的结论,尽管药物仅在经过筛选的健康老年患者中研究,不能代表真实老年人群。文中列举了向临床医生提供误导信息的报告实例,主要因耐受性和疗效未按衰弱状态评估且纳入的衰弱患者很少,并提出向临床医生、患者和卫生当局更清晰告知新抗癌药物对老年人利弊的解决方案。
要点
- 新型抗癌药物研究常仅纳入筛选后的健康老年人,不能代表真实老年人群。
- 耐受性和疗效未按衰弱状态评估,且衰弱患者纳入极少,导致误导性结论。
- 需向临床医生、患者和卫生当局更清晰说明新抗癌药物对老年人的利弊。
核心结论
- 新型抗癌药物研究常不恰当地得出在老年癌症人群中耐受良好且可行的结论。
- 这些研究仅纳入经过筛选的健康老年患者,不能代表真实老年人群。
- 耐受性和疗效未按衰弱状态评估且衰弱患者纳入少,向临床医生提供了误导信息。
研究设计与样本
- 本文为Personal View,未报告系统检索范围或样本量。
主要发现
- 多项报告因未按衰弱状态评估耐受性和疗效且仅纳入少数衰弱患者,提供误导信息。
临床怎么用
- 临床医生应警惕新型抗癌药物在老年人群中耐受良好的结论可能基于高度选择人群。
- 评估老年癌症患者时应考虑衰弱状态,而非仅依据筛选人群的研究结果。
- 需向患者和卫生当局更清晰传达新抗癌药物对老年人的获益与劣势。
局限性
- 本文为Personal View,未报告系统检索策略、样本量或定量数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Studies on new anticancer drugs often inappropriately conclude that these treatments are well tolerated and feasible in the older population with cancer, despite the drug being investigated in only a selection of healthy older patients who are not representative of the true older population. In this Personal View we outline examples of reports that provide misleading information to clinicians, mostly because the tolerance and efficacy were not assessed according to frailty status and only a few people who are frail were included. We also provide solutions on how to inform clinicians, patients, and health authorities more clearly about the benefits and disadvantages of new and upcoming anticancer drugs for older people with cancer.
引用
- Wildiers H, de Glas NA. Anticancer drugs are not well tolerated in all older patients with cancer. Lancet Healthy Longev. 2020. PMID: 36094187. doi:10.1016/S2666-7568(20)30001-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。